Welcome to our dedicated page for Yarrow Bioscience SEC filings (Ticker: YARW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Yarrow Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Yarrow Bioscience's regulatory disclosures and financial reporting.
Yarrow Bioscience, Inc. (YARW) is conducting a primary offering of 5,769,231 shares of common stock at $26.00 per share, for a gross offering size of $150,000,006, under its shelf registration statement. Underwriters hold a 30‑day option to purchase up to 865,384 additional shares. After underwriting discounts, Yarrow expects gross proceeds before expenses of $141.0 million, and estimates net proceeds of about $140.7 million, or $161.8 million if the option is fully exercised.
Shares outstanding are expected to be 8,572,309 after the base offering, or 9,437,693 if the option is fully exercised. Yarrow estimates $108.8 million in cash and cash equivalents as of August 31, 2026, up from $18.7 million as of June 30, 2026, and expects the net proceeds plus existing cash, cash equivalents and investments to fund operations into 2030, including completion of its Phase 2b Graves’ disease trial and preparatory work for its next planned thyroid eye disease study.
Yarrow Bioscience, Inc. (YARW) has filed a preliminary prospectus supplement for a primary underwritten offering of common stock and, for certain investors, pre-funded warrants to purchase common stock, together with registration of the shares issuable upon warrant exercise. Each pre-funded warrant has a de minimis exercise price of $0.0001 per share and is exercisable after issuance, subject to ownership limits.
Yarrow is a clinical-stage biotechnology company developing YB-101, a monoclonal antibody targeting the thyroid-stimulating hormone receptor for Graves’ disease and thyroid eye disease. The company preliminarily estimates cash and cash equivalents of $108.8 million as of August 31, 2026, up from $18.7 million as of June 30, 2026. Pro forma net tangible book value as of June 30, 2026 was $111.9 million, or $39.92 per share based on 2,803,078 pro forma shares outstanding.
Yarrow expects to use the net proceeds from this offering, together with existing cash, cash equivalents and investments, to fund research and development across its pipeline and for general corporate purposes. It states that these resources are expected to fund operations into 2030, including completion of its Phase 2b Graves’ disease trial and preparatory work for its next planned thyroid eye disease study, though additional capital will still be needed to reach regulatory approval and commercialization.
Yarrow Bioscience, Inc. (YARW) filed a Form 8-K to furnish an updated corporate overview and Business description following its merger with Yarrow Bioscience Operating Company Corp. and to provide an investor presentation focused on lead antibody YB-101 for Graves’ disease (GD) and thyroid eye disease (TED).
The company highlights YB-101 as a potential first-in-class anti-TSHR biologic with Fast Track Designation in GD, now in a combined Phase 2a/2b GD trial initiated in June 2026, supported by Phase 1 TED data from partner GenSci in China. Yarrow details a global license from GenSci, including a $70 million upfront payment, up to $1.295 billion in milestones, and tiered royalties in the low to low‑mid teens on ex‑China sales. The company reports $200 million raised to date and states its cash runway is expected to fund operations into 2028.
Yarrow Bioscience, Inc. has a significant shareholder group reported by ADAR1 Capital Management, LLC and Daniel Schneeberger. Private investment funds managed by ADAR1 Capital Management beneficially own 59,000 shares of Yarrow’s common stock, representing 8.8% of the class based on 668,327 shares outstanding as of June 30, 2026.
Both ADAR1 Capital Management and Daniel Schneeberger report shared voting and dispositive power over these 59,000 shares, with no sole voting or dispositive power. Schneeberger files as a control person of ADAR1 Capital Management, a Texas investment adviser, and the filing is made on a joint basis under a joint filing agreement.
venBio Global Strategic Fund V, L.P. and its general partner, venBio Global Strategic GP V, LLC, report their beneficial ownership in Yarrow Bioscience, Inc. common stock. As of July 27, 2026, they may have been deemed to beneficially own 294,139 shares, consisting of 152,881 shares held directly and 141,258 shares issuable within 60 days upon exercise of pre-funded warrants, subject to a blocker. As of the more recent reporting date, they may be deemed to beneficially own 279,340 shares, composed of the same 152,881 shares plus 126,459 shares issuable upon warrant exercise, also subject to the blocker.
These positions represent approximately 9.99% of Yarrow’s outstanding common stock at both reference dates, based on issuer-reported outstanding share counts adjusted for the exercisable warrants. The reporting persons share voting and dispositive power over 279,340 shares and have no sole voting or dispositive power.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) filed an amended report to provide full historical and pro forma financial information for the July 27, 2026 merger with privately held Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.). The company is a clinical-stage biotech developing YB-101, a monoclonal antibody targeting the thyroid stimulating hormone receptor for Graves’ disease and thyroid eye disease.
Pre-Merger Yarrow raised $100.0 million in Series A funding in December 2025 and paid a $70.0 million upfront fee to GenSci for an exclusive ex-China license to YB-101, with up to $1.295 billion in potential milestones and tiered royalties in the low to low‑mid teens. It recorded a net loss of $71.0 million from inception to December 31, 2025 and a further $9.3 million loss for the six months ended June 30, 2026.
Cash was $100.0 million at December 31, 2025 and $18.7 million at June 30, 2026, before considering $100.0 million of pre‑closing financing. Management states this liquidity is expected to fund operations for at least 12 months. The merger is accounted for as a reverse recapitalization with Yarrow as the accounting acquirer, based on an exchange ratio of 0.7171 VYNE shares per Yarrow share.
Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reports that for the six months ended June 30, 2026 it generated $0.2 million in royalty revenue and incurred a net loss of $6.6 million, a substantial reduction from $14.4 million a year earlier, primarily due to sharply lower research and development spending as legacy programs were wound down ahead of its merger with Yarrow.
Cash and cash equivalents were $22.9 million and total assets $23.6 million, with liabilities of only $1.5 million, leaving stockholders’ equity at $22.1 million as of June 30, 2026 and no debt outstanding. The company completed a strategic merger with privately held Yarrow, changed its name, effected a 1‑for‑50 reverse stock split, declared a pre‑closing $17.3 million special cash dividend, and increased authorized common shares to support its new clinical‑stage focus on YB‑101 for Graves’ disease and thyroid eye disease. Management states that, giving effect to the merger, existing cash is expected to fund operations for at least 12 months from the financial statement issuance date, and Finacea royalty revenues are expected to cease after December 31, 2026 following LEO Pharma’s license termination.
Zhang Xiaofan filed Amendment No. 3 reporting beneficial ownership of common stock of Yarrow Bioscience, Inc.. The filing states beneficial ownership of 162,452 shares of common stock, representing 0.6% of the class. These shares are reported with both sole and shared voting and dispositive power.